EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments
Organizational focus on DURAVYUTM Phase 3 DME program; trials fully enrolled with topline data expected in early Q4 2027 —— DURAVYU DME program supported by the positive Phase 2 VERONA trial and multi-MOA activity blocking both VEGF and inflammatory IL-6 pathways involved in disease pathogenesis…